Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Clin Trials ; 7(3): 256-64, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20421242

RESUMO

BACKGROUND: The ability of researchers to provide sustainable care to individuals who acquire HIV during participation in HIV prevention trials has rapidly expanded along with national treatment options. The METHODS: for Improving Reproductive Health in Africa (MIRA) trial (2003-2006), a phase III multi-site randomized controlled trial, measured the effectiveness of the diaphragm used with Replens lubricant gel in preventing heterosexual acquisition of HIV among women in Zimbabwe and South Africa. The MIRA Standard of Care program, which started towards the end of the trial period and continued for 5 months after trial closeout, enabled women who acquired HIV during the trial to receive additional counseling and clinical care and facilitated links to long-term HIV-related care and treatment from public health facilities. PURPOSE: To describe eligible participants' uptake of these optional services and evaluate the program's strengths and limitations. Methods All women who acquired HIV during their MIRA participation were re-contacted and invited to return to the study clinics for additional care and referrals. Sites reported monthly statistics of uptake of services. RESULTS: From start to end, 185 of 323 (57%) HIV-positive participants accepted additional care; 81 (25%) could not be relocated. 142 (44%) women received referrals to government healthcare facilities and 90 (28%) enrolled in wellness/ treatment programs. Fifty-seven (18%) declined further care, but reasons for doing so were not recorded systematically. LIMITATIONS: The program began after most participants had exited from the MIRA trial and required re-contacting women, resulting in difficulty in locating some participants. CONCLUSIONS: In the future, care for participants who seroconvert should be offered at the trial onset and fully integrated into clinical trials to avoid losing these participants for further care. More research is needed to identify and understand perceived barriers to establishing a continuum of care between clinical trials and public sector health facilities. Clinical Trials 2010; 7: 256-264. http:// ctj.sagepub.com.


Assuntos
Continuidade da Assistência ao Paciente , Infecções por HIV/prevenção & controle , Medicina Reprodutiva , Ensaios Clínicos Fase III como Assunto , Dispositivos Anticoncepcionais Femininos/normas , Feminino , Infecções por HIV/epidemiologia , Soropositividade para HIV/epidemiologia , Humanos , Educação de Pacientes como Assunto , Saúde Pública , Ensaios Clínicos Controlados Aleatórios como Assunto , Encaminhamento e Consulta , África do Sul/epidemiologia , Zimbábue/epidemiologia
3.
Lancet ; 370(9583): 251-261, 2007 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-17631387

RESUMO

BACKGROUND: Female-controlled methods of HIV prevention are urgently needed. We assessed the effect of provision of latex diaphragm, lubricant gel, and condoms (intervention), compared with condoms alone (control) on HIV seroincidence in women in South Africa and Zimbabwe. METHODS: We did an open-label, randomised controlled trial in HIV-negative, sexually active women recruited from clinics and community-based organisations, who were followed up quarterly for 12-24 months (median 21 months). All participants received an HIV prevention package consisting of pre-test and post-test counselling about HIV and sexually transmitted infections, testing, treatment of curable sexually transmitted infections, and intensive risk-reduction counselling. The primary outcome was incident HIV infection. This study is registered with ClinicalTrials.gov, number NCT00121459. FINDINGS: Overall HIV incidence was 4.0% per 100 woman-years: 4.1% in the intervention group (n=2472) and 3.9% in the control group (n=2476), corresponding to a relative hazard of 1.05 (95% CI 0.84-1.32, intention-to-treat analysis). The proportion of women using condoms was significantly lower in the intervention than in the control group (54%vs 85% of visits, p<0.0001). The proportions of participants who reported adverse events (60% [1523] vs 61% [1529]) and serious adverse events (5% [130] vs 4% [101]) were similar between the two groups. INTERPRETATION: We observed no added protective benefit against HIV infection when the diaphragm and lubricant gel were provided in addition to condoms and a comprehensive HIV prevention package. Our observation that lower condom use in women provided with diaphragms did not result in increased infection merits further research. Although the intervention seemed safe, our findings do not support addition of the diaphragm to current HIV prevention strategies.


Assuntos
Dispositivos Anticoncepcionais Femininos , Infecções por HIV/prevenção & controle , Cremes, Espumas e Géis Vaginais , Adolescente , Adulto , Preservativos/estatística & dados numéricos , Feminino , Infecções por HIV/epidemiologia , Humanos , Incidência , Pessoa de Meia-Idade , África do Sul/epidemiologia , Zimbábue/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...